Announcement

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence (05-21-2015)
For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in... Continue Reading

Xilonix™ Promising as Treatment for Non–Small Cell Lung Cancer (05-20-2015)
The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC). The biotechnology company XBoitech Inc recently announced clinical trial findings for the drug.[i],[ii] Xilonix... Continue Reading

Target Therapy Sutent® Promising in Advanced Thyroid Cancer (05-19-2015)
The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a... Continue Reading

Anne Arundel Medical Center

Please click here to visit the DeCesaris Cancer Institute website

The DeCesaris Cancer Institute and AAMC Oncology and Hematology are now QOPI (Quality Oncology Practice Initiative) Certified. This demonstrates a commitment to excellence and ongoing quality improvement.
The goals of the QOPI Certification Program are:

1. Promote the highest quality cancer care as defined by the clinician experts.
2. Provide a trusted solution to satisfy external demand for quality activities.
3. Reduce redundant programs or requirements for oncology practices, including health plan programs.